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Abstract 
Background: Overweight/obesity is associated with significant morbidity, 
mortality and costs. Weight loss has been shown to reverse some of these effects, 
reducing the risk of chronic diseases such as cardiovascular disease (CVD). We 
aimed to determine potential monies available, from an English National Health 
Service perspective, for weight loss interventions to be cost-effective in the 
prevention of CVD. 
Methods: A Markov model was developed, populated with overweight/obese 
individuals from the Health Survey for England aged 30-74 years, free of pre-
existing CVD, and with available risk factor information to calculate CVD risk.  All 
individuals were free of CVD at baseline and with each annual cycle, could 
transition to other health states of primary CVD, secondary CVD or death 
according to transition probabilities for a maximum period of ten years, or until 
death. Utilities, costs and the effects of weight loss on CVD risk factors were 
applied. The potential monies available for CVD prevention strategies provided 
the incremental cost-effectiveness ratio met UK arbitrary limits of between £20 
000 and £30 000 was determined. 
Results: Applying the effects of weight loss on CVD risk factors prevented 12 
CVD events and saved 12 quality-adjusted life years over 10 years per 1 000 
individuals. £27-£39 was available per person per year for up to 10 years when 
meeting the UK arbitrary limits.  
Conclusions: Individual annual financial allowances for weight loss 
interventions to be considered cost-effective is relatively low; however, as a 
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large proportion of the population is affected, wide cheap societal interventions 
are important. 
Introduction 
Overweight and obesity, which currently affects approximately 62% of the UK 
adult population [1], is linked to many chronic diseases such as cardiovascular 
disease (CVD), diabetes and cancer. The significant morbidity and mortality 
associated with overweight and obesity imposes a major burden on the 
healthcare system.  The UK Foresight report estimated that in 2007, the annual 
direct costs to the National Health Service (NHS) of treating overweight and 
obesity, and related morbidity, was approximately £4.2 billion in England alone 
[2] and more recently the McKinsey report has estimated the global burden as 
equivalent to $2 trillion annually [3].   
 
Weight loss, even when modest or unsustained long-term, has been shown to 
reverse some of the effects of overweight and obesity, and in turn reduce the risk 
of chronic diseases such as type 2 diabetes [4] and cardiovascular disease (CVD) 
[5, 6]. Weight-loss interventions include lifestyle interventions (diets to reduce 
energy intake, increased exercise or physical activity, or their combination) as 
well as pharmaceutical and bariatric surgical interventions. Just as the extent of 
weight loss differs between interventions, so too do the costs. For example, 
bariatric surgery which involves invasive surgery and hospitalization is initially 
much more expensive than pharmaceutical therapy, which is in turn more 
expensive than most lifestyle interventions. Whilst cost-effectiveness analyses to 
investigate the cost-effectiveness of specific interventions in the prevention and 
treatment of obesity and its related disease have been undertaken, the cost-
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effectiveness of weight loss (irrespective of the type of intervention used) has 
not been evaluated as an integrated whole. In this study, we aim to determine the 
amount of monies available, from an English NHS perspective, for weight loss 
interventions to be considered cost-effective in the prevention of cardiovascular 
disease with a particular focus on interventions that result in moderate (5-
<10%) weight loss. 
 
Methods 
An individual level Markov model was developed in Microsoft Excel to determine 
the potential monies available for weight loss interventions to be considered 
cost-effective. In the model, all individuals enter in a healthy state, free of CVD. 
Individuals then, on a random basis, transition to another cardiovascular health 
state according to transition probabilities derived from risk prediction 
algorithms, and population life-tables. Individuals continue to cycle through the 
model yearly until the time-point of interest is reached. We chose a period of 10 
years, in line with current CVD risk prediction algorithms, unless the individual’s 
trajectory leads to earlier death. The possible health states to which an 
individual could transition can be depicted using a decision-analysis tree (Figure 
1).  Possible designated resulting states include: alive without cardiovascular 
disease, alive with cardiovascular disease, dead from cardiovascular disease or 
dead from other causes. Thus, with each annual cycle, an individual may develop 
non-fatal cardiovascular disease, or die from cardiovascular disease or other 
non-cardiovascular causes. All events were considered to occur halfway through 
an annual cycle.  
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Transition probabilities 
Primary CVD 
The annual risk of a primary CVD event was determined using the Framingham 
risk prediction algorithm [7]. This algorithm uses risk factors of age, sex, systolic 
blood pressure, total cholesterol, high-density lipoprotein (HDL)-cholesterol, 
smoking status, diabetes status and the presence or absence of left ventricular 
hypertrophy (LVH) to determine risk. The impact of obesity is implicitly included 
in the algorithm. This risk, together with a random number generator, 
determines which individuals will in fact have an event. For example, if a 
patient’s probability of a primary CVD event in a cycle is 0.176 (17.6%) and the 
random number generated is 0.163 (16.3%), the patient is assumed to have a 
primary CVD event. If the random number is 0.53 (53.0%), however, the primary 
CVD event does not occur. Once an individual is classified as having a primary 
CVD event, the event is proportioned out into different types of CVD events 
including unstable angina, stable angina, CHD, CHD death, transient ischaemic 
attack (TIA), stroke, and stroke death, according to age and sex, as per 
distributions in the ScHARR model [8]. With each annual cycle, annual changes in 
modifiable risk factors such as systolic blood pressure, total and HDL-
cholesterol, as well as BMI were also applied. These annual changes were 
calculated using the evidence from the Health Survey for England [1] and 
Framingham risk was re-calculated.  
 
Secondary CVD 
The risks of secondary events were sourced from a Health Technology 
Assessment report for an economic evaluation of statins for the prevention of 
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coronary events [8], which provided annual transition probabilities by age and 
sex. These risks were dependent on the type of primary CVD event (e.g. CHD or 
stroke event), and included secondary non-fatal MI, non-fatal stroke, fatal MI and 
fatal stroke.  
 
Death from other causes 
The risk of dying from other causes was determined using data from the Office 
for National Statistics 2010 for England and Wales only [9], calculated as the 
difference between all-cause mortality and circulatory deaths. This was stratified 
by age and sex.  
 
Population  
Individual subject data was gathered from the Health Survey for England [1] in 
2011. Only those of adult age 30 to 74 years old in keeping with the Framingham 
risk prediction algorithm age specifications, free of pre-existing CVD, who were 
overweight/obese (BMI >25 kg/m2), and with all necessary risk factor 
information available to calculate risk of CVD according to the Framingham risk 
prediction algorithm were included, with the exception of LVH which is not 
routinely collected and therefore was assumed to be absent in all individuals. 
Changes in modifiable risk factor levels were calculated using the Health Survey 
for England 2008-2011 data, stratified by BMI, sex, and 10-year age bands. From 
these, annual changes within age-bands were derived assuming linear changes. 
Since the absolute risk of CVD is low in a young adult population, we also 
undertook a sub-group analysis in a population 40 years and older. A sub-group 
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analysis stratified by BMI was also undertaken to assess the effects of weight loss 
in each weight category. 
 
Effect of weight loss 
Data on the effect of weight loss on CVD events as such are limited. There is, 
however, extensive evidence on the impact of interventions that cause weight 
loss on cardiovascular risk factors. We recently conducted a systematic review 
and meta-analysis on the effect of interventions that cause weight loss on 
cardiovascular risk factors at different time points (6-<12 months, 12-<24 
months, and >24 months) [10]. We excluded bariatric surgery as this causes 
extreme and rapid weight loss, is only appropriate in severely obese individuals, 
and only a very small minority are able to access it [11]. In our model, we only 
included the risk factor effects present in the Framingham risk prediction 
algorithm (systolic blood pressure, total cholesterol, and HDL-cholesterol). The 
effects of interventions that cause weight loss on cardiovascular risk factors 
were stratified by different degrees of percentage weight loss (0-<2.5%, 2.5-
<5%, and 5-<10%). Sub-analyses assessed the effect of percentage weight loss on 
cardiovascular outcomes, assuming 100% compliance.  Input data, however, 
came from our meta-analysis, where the percentage weight loss encapsulated 
participants that did not have a 100% compliance or success with weight loss 
interventions. See Table 1 for input values. Interventions which extended beyond 
24 months’ time point were typically 24-<36 months in duration. For cycles in 
the model after 36 months (4-10 years), both a best and worst-case scenario was 
explored. In the first instance the effects of weight loss on cardiovascular risk 
factors were set to zero i.e. that there were no subsequent effects associated with 
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the weight loss on cardiovascular risk factors (a conservative estimate). In the 
second analysis, the effects of weight loss on cardiovascular risk factors were 
assumed to remain the same throughout the 10-year period as those observed at 
24 months.  
 
Utilities 
All individuals in the model were assigned a quality of life value or utility 
according to their BMI; which was age- and sex-specific. If they were deemed to 
have a cardiovascular event, the utility decrement associated with the 
cardiovascular event was then applied (see Table 2) [8]. 
 
Costs 
Costs of cardiovascular events were taken from the ScHARR cost-effectiveness 
model and were based on a thorough review of the most recent and appropriate 
costing information [8]. They are summarised in Table 2. Costs included direct 
costs of myocardial infarction, stable and unstable angina, stroke, transient 
ischaemic attack (TIA), as well as fatal CHD and fatal stroke, measured for the 
first year of the event and after the first year. All costs were inflated from 
2004/2005 values to reflect 2015 costs according to the UK national health price 
index [12]. All future benefits (QALYs) and costs were discounted at 3.5% per 
annum.  
 
Outcomes 
The outcomes of interest we studied were the number of QALYs prevented and 
the potential monies available for prevention strategies provided the 
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incremental cost effectiveness ratios (ICERs) met arbitrary limits set out in terms 
of UK pounds per year per QALY saved. We calculated ICERs by comparing the 
difference in net costs between treatment (weight loss) and no treatment 
(control), divided by the difference in QALYs lived by each cohort. The arbitrary 
threshold for ICERs is between £20 000 and £30 000 [13]. We employed both 
threshold limits to determine the potential monies available for prevention 
strategies over 10 years.  
 
Results 
1 544 individuals from the Health Survey for England 2011 met the criteria for 
inclusion in the model. The average age of these individuals was 53 years 
(standard deviation (SD) 12.1), 52.4% of whom were female. The average BMI 
was 30.1 kg/m2 (SD 4.4). Cardiovascular risk factors were slightly elevated 
[systolic blood pressure: 128.9 mmHg (SD 16.0); HbA1c: 5.8% (SD 0.8); total 
cholesterol: 5.5 mmol/L (SD 1.1)], with the exception of HDL-cholesterol, which 
was above the accepted mean normal value (1.1 mmol/L) measuring 1.4 mmol/L 
(SD: 0.4).  12.0% of the population were smokers and 6.3% had diabetes.  
 
When the effects of weight loss (see Table 1) on CV risks were applied to the 
individuals included in this model, 12 cardiovascular events were prevented, 12 
QALYs were potentially saved over 10 years per 1 000 individuals when the 
effects after 36 months were set to nil, and 20 cardiovascular events were 
prevented and 42 QALYs saved when the effects after 36 months were set to that 
seen at >24 months, compared to placebo. Based upon a cost-effectiveness 
threshold of £20 000/QALY, the potential monies available to provide a weight 
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loss intervention would be £27.42 and £91.63 per person per year for up to ten 
years respectively. At a £30 000/QALY threshold, the cost of cost-effective 
interventions would be £39.02 and £133.94 respectively. 
 
When weight loss was stratified by percentage weight loss (0-<2.5%, 2.5-<5%, 5-
<10%), the number of cardiovascular events prevented, the number of QALYs 
saved and the potential monies available increased with increasing weight loss 
(Table 3).  In line with the results seen in the main analysis, when the treatment 
effects after 36 months were set to maintain 24-<36 months outcomes, the 
number of CVD events prevented, number of QALYs saved and potential monies 
available were greater than when they were set to the conservative scenario of 
no sustained weight loss effects.  
 
Applying the effects of weight loss on CV risks to an older population of adults 
aged 40 to 74 years, prevented more cardiovascular events than when the whole 
population was included (Table 3).  
 
Applying the effects of weight loss to only those who were only overweight 
prevented slightly more events than when both overweight and obese were 
included, but with lower annual permitted expenditures (Table 4). The reverse 
was seen when the effects of weight loss were applied to only those who were in 
the obese category. 
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Discussion 
Weight loss has been shown to reduce cardiovascular risk factors, events and 
improve quality adjusted life years [10]. In England the provision of short-term, 
non-clinical weight management (so-called Tier 2 services) are commissioned at 
a cost of between <£50 to £400 (most frequently reported £100/participant) 
[14]. Tier 3 services represent more complex interventions, clinically led, 
targeted at those with severe and/or complex obesity, but are very scanty. 
Where they exist, the cost is reported to be >£400/patient [14].  We have 
explored what sums of money could be spent on weight loss interventions that 
would meet NICE criteria for cost-efficacy [15]. 
 
Interventions that cause weight loss could potentially gain between 10 and 26 
QALYs for a population of 1 000 individuals aged 30 to 74 years who were 
overweight/obese and free of existing CVD, over 10 years. According to the 
arbitrary thresholds of affordability equal to £20 000 to £30 000 per QALY 
gained, between £27 and £134 could potentially be spent per person each year 
for up to ten years on weight loss interventions. When weight loss was stratified 
by percentage weight loss (0-<2.5%, 2.5-<5%, 5-<10%), greater reductions in 
weight resulted in more QALYs gained and therefore the potential for greater 
financial inputs for prevention strategies. As expected, when the effects after 36 
months were constant and remained the same as at 24-<36 months, the results 
were more pronounced than when the effects after 36 months were set to null. 
However, this was not apparent when the effects of 5-<10% weight loss were 
considered. This finding may simply reflect the absence of data obtained in the 
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systematic review for the long term effects of sustained 5-<10% weight loss 
rather than something specific to this greater weight loss achievement. 
Furthermore this scenario is likely to be overly conservative since there is clear 
evidence from a number of lifestyle intervention programs that benefits of 
diabetes prevention persist in the long-term [16]. 
 
Unsurprisingly, analysis of the older age group (age 40 to 74 years), 
demonstrated that a greater number of cardiovascular events could be 
prevented when the benefits after 24 months were maintained, compared to the 
whole population of 30 to 74 year olds. The number of QALYs saved, were also 
greater. Since CV events in younger age groups are fewer than in older adults, 
this finding may change if whole lifetime benefits (rather than a 10 year follow-
up) were to be modelled. Furthermore if adults >75 years were included, then 
their far higher absolute risk could potentially have enhanced the benefits over a 
subsequent decade of weight loss and reduced cardiovascular risk. However the 
Framingham risk prediction algorithm excluded those older than 74 years. 
 
Our model has demonstrated that the potential monies available for weight loss 
strategies in the prevention of CVD can range from £27 to £134 per person per 
year for ten years, dependent on the population, amount of weight loss, long-
term effects of weight loss, and cost-effectiveness threshold employed. Whilst 
many intervention strategies have been reported as far dearer than this [17, 18], 
this amount is within current spending on Tier 2 services in England.  
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Our findings therefore support ‘investment’ in making access to treatment 
programmes more readily available, even if they produce ‘only’ modest weight 
losses of about 5%, and even if this weight is not sustained long-term. This may 
include relatively cheap community wide wellness programs such as free or 
subsidised exercise classes [19]. As the risk of overweight and obesity escalates 
with age there will be greater justification for applying rather more expensive 
interventions for this older portion of the population. 
 
Several analyses have been made of the benefits and cost-efficacy of 
pharmaceutical interventions [20, 21]. Benefits are wider than just those on the 
cardiovascular effects analyzed in this modelling exercise. Interestingly the 
application of ‘stopping rules’ (i.e. discontinuing medication) in non or poorly 
responding patients is now widely included in the regulatory approval process 
and can enhance safety, efficacy and cost-efficacy. Regulatory measures which 
aim to change the nature of societal eating patterns by imposing checks and 
taxes on advertising of inappropriate foods and drinks, taxing sugary drinks and 
fast foods are all capable not only of raising government revenue but, if they 
allow even modest weight loss on a population basis, important costs savings for 
the health services. Purely on a cardiovascular basis the benefits are likely to be 
great provided the costs of implementation through regulatory measures are 
small for governments.  If these and additional measures which reduce 
hypertension and population lipid levels (e.g. by continuing to reduce salt [22] 
and saturated fat intakes)  are implemented, the benefits in reducing 
cardiovascular disease will be amplified.  
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A number of features of our study limit its robustness. First, although the 
Framingham algorithms are widely accepted, they do not always predict 
cardiovascular events in other populations accurately. Furthermore these 
algorithms generated from a general population in practice underestimate 
cardiovascular risk in some higher-risk populations, such as those with diabetes. 
It is also clear that without long-term data on the overall impact of weight loss 
interventions on cardiovascular events it is unclear whether the benefits are 
cumulative, progressively increase, or decrease. Therefore in our analyses we 
performed an assessment of the impact of interventions that cause weight loss 
on cardiovascular risk over an extended duration, on both a best and worst-case 
basis. When we assumed conservatively that there were no further benefits after 
36 months of weight loss, this worst case scenario limited the scale of the benefit. 
However, a recent study [23] found that any weight  loss, even if not sustained, 
was associated with decreases in carotid intimal thickness and improvements in 
the cardiovascular risk-factor profile, suggesting that weight loss, at any age in 
adulthood, is worthwhile and could result in long-term cardiovascular benefit. 
This so-called ‘memory effect’ of weight loss has been well demonstrated in a 
number of diabetes prevention programmes [24, 25, 26, 27] and suggests that 
interventions that are not sustained may still have profound and long-lasting 
value.  
 
A further limitation of our model pertains to our model population who may not 
be representative of the general UK population. Whilst our population was 
sourced from a national health survey, our rates of smoking were lower than 
observed in the larger Health Survey for England dataset, the General Lifestyle 
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Survey and the Smoking Tookit Study [28]; this may reflect some selection bias 
as individuals with any missing variable data were excluded. Our population, 
therefore may be ‘healthier’ than the general population. Employing a ‘lower’ 
risk population in our model could result in an underestimation of the true cost 
effective benefits of weight loss interventions in the UK. 
 
Finally, the effects of weight loss on other outcomes was also not included. 
Weight loss has been shown to be beneficial for other outcomes such as cancer, 
osteoarthritis and depression [29, 30, 31, 32]. The reduction in disease would 
not only decrease costs associated with treatment, but also improve the quality 
of life for the individual. The omission of other weight loss outcomes in our 
model further adds to the conservative estimate of the true effectiveness and 
cost-effectiveness of weight loss interventions in the UK. 
 
Conclusions 
The findings from this study demonstrate circumstances under which 
interventions that cause weight loss may be cost-effective in the prevention of 
CVD.  The individual annual financial allowance for selective cardiovascular 
preventive measures from weight loss alone is small to gain savings in health 
care costs, but still higher than is being spent by public health and clinical 
commissioning groups at present. However, with such a large proportion of the 
population overweight or obese and with cardiovascular disease still the major 
cause of death and disability, the need for population wide cheap societal 
interventions to limit weight gain and encourage weight loss are particularly 
important and could substantially reduce the health services costs.   
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Figure 1: Potential progressive health states during the 10 years of the  model. 
 
Table 1 Input parameters including the changes in cardiovascular risk factors 
associated with interventions that cause a) any weight loss, b) 0-<2.5% weight 
loss, c) 2.5-<5% weight loss, d) 5-<10% weight loss and e) any weight loss 
restricted to those aged >40 years 
a) 
 Year
 1 2 3
SBP (mmHg) -2.675 -1.570 -1.549 
TC (mmol/L) -0.247 -0.092 -0.076 
HDL-C (mmol/L) 0.003 0.005 0.039 
BMI (kg/m2) -0.776 -1.247 -0.752 
 
b) 
 Year
 1 2 3
SBP (mmHg) -2.102 -1.395 -2.236 
TC (mmol/L) -0.103 -0.154 -0.096 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
HDL-C (mmol/L) 0.007 0.007 0.020 
BMI (kg/m2) -0.448 -0.456 -0.352 
 
c) 
 Year
 1 2 3
SBP (mmHg) -3.025 -1.707 -0.666 
TC (mmol/L) -0.582 0.039 -0.034 
HDL-C (mmol/L) 0.010 0.007 0.050 
BMI (kg/m2) -0.881 -1.001 -0.969 
 
d) 
 Year
 1 2 3
SBP (mmHg) -4.861 -1.417 -0.790 
TC (mmol/L) -0.672 -0.431
HDL-C (mmol/L) -0.079 0.013 0.044 
BMI (kg/m2) -1.579 -2.209
 
e) 
 Year
 1 2 3
SBP (mmHg) -2.439 -1.570 -1.582 
TC (mmol/L) -0.268 -0.092 -0.077 
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HDL-C (mmol/L) 0.006 0.005 0.030 
BMI (kg/m2) -0.751 -1.247 -0.472 
SBP: systolic blood pressure; TC: total cholesterol; HDL-C 
: high-density lipoprotein cholesterol; BMI: body mass index; and changes in BMI 
associated with weight loss were only included for annual changes in risk factors 
and determination of utility purposes. 
Table 2: The cost at the time of the event and in subsequent years of having had 
different types of cardiovascular events, and the respective annual QALY 
decrement subsequent to the year of having an event.  
Input variable Costs (£) QALY decrement Source 
 Year 1 Subsequent years  
MI 5 615 216 -0.072 8 
Stable angina 216 216 -0.126 8 
Unstable angina 555 216 -0.126 8 
Stroke 10 156 2 730 -0.185 8 
TIA 1 343 333 -0.088 8 
Fatal MI 1 472 8 
Fatal stroke 8 888 8 
MI: myocardial infarction; TIA: transient ischaemic attack; all costs were 2015 
costs (inflated from 2004/05 costs as per the UK National Price Index). 
 
Table 3: Differences in the number of primary and secondary events and the 
quality-adjusted life years (QALYs) gained from different degrees of weight loss 
for 1 000 individuals over ten years. The potential monies available for 
prevention of cardiovascular disease (CVD ) to ensure cost savings for 
interventions that cause weight loss and its effect on cardiovascular risk factors 
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is set out assuming either only short term benefits for the first 36 months of 
weight loss (nil effects) or continuing benefits for the whole 10 year period 
(same effects).  
 
 Number of 
Primary CVD 
events 
 
Number of 
Secondary 
CVD events 
QALYs 
gained 
Annual permitted 
expenditure at two 
different Cost-
effectiveness thresholds 
£20 000 £30 000
30-74 year population with any weight loss
Nil effects 7 5 12 27.42 39.02 
Same 
effects   
13 7 42 91.63 133.94
    
Percentage weight loss 
0-<2.5%     
Nil effects 7 5 4 11.83 15.64 
Same 
effects   
13 7 21 48.88 69.82 
2.5-<5%    
Nil effects 8 5 14 32.57 46.38 
Same 
effects   
14 8 52 111.85 164.04
5-<10%   
Nil effects 9 5 26 56.30 81.94 
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Same 
effects   
12 7 29 63.96 92.68 
    
40 -74 year population with any weight loss
Nil effects 8 6 14 33.54 47.88 
Same 
effects   
15 9 47 102.48 149.58
 
Where any weight loss represents any weight loss (0->10% change in body 
weight); nil effects represents zero effect of weight loss on cardiovascular risk 
factors after 3 years; same effects represents same effects of weight loss on 
cardiovascular risk factors after 3 years as  at year 3. 
 
 
Table 4: Differences in the number of primary and secondary events and the 
quality-adjusted life years (QALYs) gained for 1 000 overweight/obese 
individuals over ten years, stratified by starting BMI. The potential monies 
available for prevention of cardiovascular disease (CVD ) to ensure cost savings 
for interventions that cause weight loss and its effect on cardiovascular risk 
factors is set out assuming either only short term benefits for the first 36 months 
of weight loss (nil effects) or continuing benefits for the whole 10 year period 
(same effects).  
 
 Number of 
Primary CVD 
events 
 
Number of 
Secondary 
CVD events 
QALYs 
gained 
Annual permitted 
expenditure at two 
different Cost-
effectiveness thresholds 
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£20 000 £30 000
BMI 
25-<30 
kg/m2  
  
Nil effects 9 4 0 3.81 3.58 
Same 
effects   
15 6 28 63.52 91.76 
30-<40 
kg/m2 
  
Nil effects 4 0 20 42.03 61.54 
Same 
effects   
9 4 56 116.46 172.01
 
Where nil effects represent a zero effect of weight loss on cardiovascular risk 
factors after 3 years; same effects represent the same effects of weight loss on 
cardiovascular risk factors after 3 years as at year 3. 
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